Neurology News

People experiencing persistent post-concussion symptoms were at a higher risk for depressive symptoms, researchers reported in JAMA Network Open.

Biomind Labs has completed the development of a novel sublingual formulation to be used in a phase 2 trial for a psychedelic-based candidate for the treatment of depression and anxiety in patients with Alzheimer’s disease.

An association between common antiepileptic drugs and incident Parkinson’s disease was found, researchers reported in JAMA Neurology.

The FDA has issued a complete response letter to Ipsen for its new drug application for palovarotene, an investigational treatment for the reduction of new abnormal bone formation in people with fibrodysplasia ossificans progressiva.

KGK Sciences Inc. received a no objection letter from Health Canada to proceed with a phase 2a clinical trial evaluating the use of psilocybin for fragile X syndrome, the leading genetic cause of autism spectrum disorder.

Traumatic brain injury, PTSD and the apolipoprotein E4 gene showed strong associations with Alzheimer’s disease and related dementias, researchers reported in Alzheimer’s & Dementia.

Cebranopadol, a pain relief drug, showed low potential for abuse among nondependent recreational opioid users compared with tramadol or oxycodone, researchers from Tris Pharma Inc. stated in a press release.

Although cluster headaches may be more common in men, they may be more severe for women, researchers reported in Neurology.

Click Therapeutics announced it has received breakthrough device designation from the FDA for its digital therapeutic, CT-132, as an adjunctive preventive treatment for episodic migraines in those aged 18 years and older.

Individuals with prodromal or unrecognized Parkinson’s disease may have greater impairment involving mobility and strength up to 3 years prior to diagnosis, researchers reported in JAMA Neurology.